Letter to Utah Congressional Delegation RE: H.R. 3, The Lower Drug Costs Now Act
May 25, 2021
Today, BioUtah, in conjunction with Centro Civico Mexicano, First Step House, International Cancer Advocacy Network, Mental Healthy FIT, Northern Utah Coalition, and Patel Family Investments, sent a letter to Utah’s congressional delegation expressing concern with the reintroduction of H.R. 3, The Lower Drug Costs Now Act. In the letter, the coalition states its concern about the bill’s negative impact on investment in drug discovery.
You may read the letter in its entirety here.
Recent News
- Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA Initiation in Adults with IBS-C
- Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
- Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
- Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
- BlueWind Medical Announces Humana Coverage of Revi® for Urgency Urinary Incontinence, Expanding Access to Millions of Patients
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
